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ABSTRACT
VALIDITY OF WHOLE AND REGIONAL BODY
COMPOSITION TESTING
DEVICES
Alexa R. Suida, M.S. Ed.
Department of Kinesiology and Physical Education
Northern Illinois University, 2016
Amanda Salacinski, Thesis Director

Obesity has been established as a risk factor for multiple diseases and is an increasing problem
throughout the world. Advances in technology have enabled health professionals to use many
devices to diagnose individuals as healthy, overweight, or obese. However, there are
discrepancies between the validity of the devices. PURPOSE: The purpose of this study is to
validate InBody 520 and InBody S10 against the Hologic dual-energy X-ray absorptiometry
(DXA) system. METHODS: 50 male and female subjects performed body composition testing
on an InBody 520, InBody S10, and a Hologic DXA, followed by repeat measurements on the
InBody 520 and S10. RESULTS: Body fat percentage was significantly greater for the DXA
when compared to the InBody 520 (p<.001) and significantly greater when compared to the the
InBody S10 (p=.0006). Lean body mass was significantly less for the DXA when compared to
the InBody 520(p=.0362) but not significant when compared to the InBody S10 (p=.0961). Body
fat mass was significantly greater for the DXA compared to the InBody 520 (p=.0156) but not
significant when compared to the InBody S10 (p=.0909). CONCLUSION: The InBody devices
were not significantly different in measuring body fat mass, lean body mass, and percent body
fat, but were different when compared to the DXA for the lean body mass and percent body fat.
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CHAPTER 1

INTRODUCTION

Obesity, a condition experienced by individuals that possess excessively accumulated
amounts of fat tissue, is an increasing public health problem within the Unites States and much
of the developed world (Ehrman, Gordon, Visich, & Keteyian, 2013). Being overweight is
defined by National Institutes of Health(NIH) as a body mass index (BMI) of greater than 25 and
obese is characterized as BMI greater than 30 (Gilmore, 1999). The amount of individuals whom
are considered obese has exponentially increased in the United States over the last 40 years
(Center for Disease Control, 2015). As of 2015, more than one third of the adults in the United
States are considered obese (Center for Disease Control, 2015). Based on data collected from
1976-1980 and 1988-1994, obesity rates increased 7.9% for males and 8.9% for females, and
further research from 1999-2000 has that obesity rates had once again increased another 7.1% for
males and 8.1% for females (Ogden, Carroll, Kit, & Flegal, 2014).
Obesity levels have significantly increased for the last three decades and recent data from
2000 to 2008 reveals that males exhibited an increase of 4.7%, but female obesity occurrence
non-significantly increased by only 2.1% during this time (Ogden et al., 2014). Although obesity
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rates in women have begun to demonstrate a reduced incidence, the overall epidemiological rates
remain at a high level for the entire Unites States population (Ogden et al., 2014). Obesity rates
are not only high in the United States but across the world as well. In Canada, as of 2009, 27.6%
of all adult men and 23.5% of all adult women are obese (Kenney, Wilmore, Costill, 2012). In
Mexico, as of 2006, 24.2% of adult men and 34.5% of adult women are obese (Kenney et al.,
2012). The overbearing amount of Americans suffering from obesity is such an issue because
obesity is associated with health risks related to specific diseases such as cardiovascular disease
(CVD), Type II Diabetes(T2DM), and hypertension (Ogden et al., 2014).
Obesity has well been established as an independent risk factor for cardiovascular disease
(CVD) and this has been demonstrated through the Framingham Heart Study (Hubert, 1983).
Certain types of obesity, such as central or visceral adiposity, have high correlations with an
increased risk for the development of CVD (Hubert, 1983). CVD is caused by the progression of
advanced atherosclerosis, or plaque build up, in at least one coronary artery (American College
of Sports Medicine, 2014). Atherosclerosis is caused by lipid build up that causes an injury to the
endothelial lining of an artery wall (American College of Sports Medicine, 2014). Coronary
atherosclerosis involves a localized accumulation of lipid and fibrous tissue with the coronary
artery, progressively narrowing the lumen of the vessel (Brill, 2012, American College of Sports
Medicine, 2014). The development of atherosclerosis can result from the interaction of genetics,
poor lifestyle choices and environmental influence that are collectively known as risk factors
(Kannel, 1961). As this process continues to progress with continued inflammation from any one
of the many factors such as elevated free fatty acids in the blood due to excess adiposity, fatty
streaks finally progress over time to form fibrous plaques consisting of LDL-C cholesterol and
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macrophages which eventually lead to an atheromata (Kannel, 1961). This atheromata blockage
can finally lead to cardiovascular complications such as myocardial infarction or hemorrhagic
stroke.
Obese individuals, especially those with high visceral fat accumulations are also at higher
risk for developing Type II diabetes (ACSM, 2014). Type II diabetes (T2DM) sometimes
displays a reduced binding affinity of the insulin receptor (Codario, 2005). Whether or not an
individual has this inadequate binding affinity, those with T2DM will have too much glucose
excreted from the liver resulting in insulin resistance (Codario, 2005). Insulin resistance is a
condition in which the cells of the body become less responsive to initiating GLUT-4 transport
activation to the cell membrane. Resistance to insulin-stimulated glucose uptake is a common
phenomenon and plays a central role in the pathogenesis and clinical course of several important
human diseases (Reaven, 1988). Skeletal muscle insulin resistance is associated with obesity and
physical inactivity and is crucial for the development of T2DM (Saltiel, 2000, Amati, 2011).
When the body is insulin resistant, the muscles cannot take up the glucose as it should and this
results in a lower amount of glucose being disposed (Codario, 2005).
In a fasting state, skeletal muscle is highly reliant on fatty acid oxidation. Upon
stimulation by insulin, glucose oxidation is enhanced and fatty acid oxidation is suppressed and
this flexibility in fuel metabolism has been termed metabolic flexibility. In individuals with
obesity or T2DM, they tend to demonstrate a decreased lipid oxidation during fasting and in
response to insulin show impaired metabolic flexibility (Chomentowski, 2010). Impaired
metabolic flexibility results in the body continuously producing too much insulin to compensate
for the insulin resistance and the beta cells of the pancreas eventually become exhausted from
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overworking for an extended period of time. Eventually, pancreatic function declines to a point
that the amount of insulin produced is inadequate and normal glycemic control is severely
impaired. When the beta cells cease to produce required insulin, blood glucose levels begin to
rise. T2DM eventually results from the continuous increase of blood glucose levels (Becker,
2001).
When individuals experience an energy imbalance such as consuming more energy than
expelled, eventually the excess energy will be stored within the fat cells in the body. Excess
storage within the fat cells causes the fat cells to either enlarge (hypertrophy) or multiply
(hyperplasia) resulting in obesity over time. When this energy imbalance is consistent, insulin
resistance occurs. Thus, obesity itself is an independent risk factor for insulin resistance because
of ectopic adiposity. Ectopic adiposity is when fatty acids begin to accumulate within nonadipose tissue throughout the body (Ehrman et al., 2013). If untreated, ectopic adiposity leads to
dysfunction within the mitochondria of the muscles causing a decreased lipid oxidation and lipid
metabolites accumulate, which will continue to increase insulin resistance.
According to ACSM, approximately 75% of hypertension cases are due to obesity. The
pathophysiology of “essential hypertension” is still relatively unknown but several factors such
as increased sodium intake from diet, obesity, insulin resistance, sympathetic nervous system
complications, and the renin-angiotensin system have been linked to the increase in blood
pressure (Beevers, Lip, O’Brien, 2001). The relationship between hypertension and excess body
weight has long been recognized in the medical community (Hubert, 1983) and this relationship
has been demonstrated in large cross-sectional studies that have observed the relation between
blood pressure level and the individuals body weight. The ACSM has identified being
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overweight or obese as a main risk factor for hypertension and states that a decrease of body
weight by as little as 5% can significantly lower blood pressure levels. In addition to obesity
related risk factors, there are multiple other aspects that make up an individual’s body
composition.
Body Composition
Body composition is the measurement of body tissues such as muscle mass, soft tissue,
body fat, water composition and bone mineral density (Heymsfield, Lohman, Wang, & Going,
2005). In determining body composition, it is important to differentiate between fat mass and
muscle mass. Fat mass is all the soft tissue in the body that is composed of fat or adipose tissue.
Fat mass is typically discussed in regards to percentage of body fat within the body. In addition
to BMI and classifying individuals as obese, there are set markers of body fat percentage that
identify individuals as normal, overweight, or obese. Men containing more than 25% body fat
and women containing more than 35% should be considered obese (Kenney et al., 2012).
Muscle mass plays a significant role in obesity as well. Within the three types of muscle
tissue; skeletal, cardiac, and smooth, the main focus related to obesity lies with skeletal muscle
tissue (Plowman & Smith, 2014). Skeletal muscles are made up of different fiber types based on
varying characteristics such as contractile or metabolic properties (Plowman & Smith, 2014).
Based on contractile properties, muscle fibers are split up into either fast twitch or slow twitch
categories (Plowman & Smith, 2014). Slow twitch fibers are also known as Type I while fast
twitch are also known as Type II muscle fibers. Type I fibers contract and relax slowly while
Type II fibers contract and relax quickly (Plowman & Smith, 2014). Based on metabolic
properties, muscle fibers are either glycolytic, oxidative, or a combination of both (Plowman &
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Smith, 2014). Type I fibers are primarily oxidative fibers meaning they rely heavily on oxidative
metabolism for energy. Type II fibers can be both because broken down to their subunits, Type
IIa fibers use both oxidative and glycolytic metabolism for energy but Type IIx fibers rely
primarily on glycolytic metabolism for energy. Muscle mass and fat mass are not the only
biological components that affect body composition.
Increases in non-metabolic tissue (fat mass) significantly correlate with increased health
risks in different populations (Heymsfield et al., 2005). Conversely, individuals with more lean
tissue (fat free mass) have been shown to have lower health risks due to a lower quantification of
body fat mass due to an increased amount of muscle mass (Heymsfield et al., 2005). By
measuring body composition, health researchers can group individuals of different populations
into sub-categories and use this grouping to organize and recognize the most prominent risk
factors that are present and determine which one has the greatest effect on overall health for
subjects who are lean, overweight, or obese.
In addition to different levels of muscle or fat mass, body composition values can be
affected by gender, age, and ethnicity. Body composition measurements vary between genders
with females tending to have higher levels of body fat due to the requirement of essential fat for
normal physiological functions (McArdle, Katch, & Katch, 2015). Increased amounts of
essential body fat have been linked to biological functions such as childbearing (McArdle,
Katch, & Katch, 2015). Men tend to have more muscle mass than women, which is theorized to
be associated with an increased total body water composition and an increased protein and
mineral content compared to females. (Heymsfield et al., 2005).
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Aging impacts body composition from the day that we are born. From the age of 9 to 20,
females’ body fat percentage will increase to around 20 to 26% but conversely body fat in boys
will decrease to around 17% to 13% after they turn thirteen years of age. Decreased fat mass in
boys is believed to be attributed to as boys continue to grow, their fat free mass increases at a
greater rate compared to females. (Heymsfield et al., 2005). During the maturational change
from adolescence to adulthood, body fat percentage tends to increase per year. For females, body
fat percentage increases approximately 0.41 kilogram per year and males also increase
approximately 0.37 kilograms per year (Heyward & Stolarczyk, 1996). While this increase in
body fat is typically seen across the first two decades of growth we also have another trend of a
decreased body density that begins to occur after our third decade of growth.
Lastly, ethnicity has an effect on body composition. The greatest difference from the
“white reference model” is seen among African Americans. The reference model assumes that
body density is 1.10 g/cc but it is now known that African American males and females differ
from this body density value. African American males body density is 1.113 g/cc and African
American females body density is 1.106 g/cc (Heyward & Stolarczyk, 1996). These differences
are a result of higher mineral contents in African Americans compares to the reference model.
It is hypothesized that as we age, our body density decreases due to the decrease in
skeletal protein content and the increase in body fat, thus changing our overall body composition
contributing to the onset of sarcopenia-obesity. Sarcopenic-obesity is the decrease in skeletal
muscle mass and increase in body fat with the natural aging process. Sarcopenia risk factors
include sedentary lifestyle, morbidity, smoking, and malnutrition (Fielding, Vellas, Evans,
Bhasin, Morley, Newman, ... & Cederholm, 2011). Once sarcopenia sets in, individuals are at an
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increased risk of falls, fractures, and immobility. The main consequences of sarcopenia include
decreased resting energy expenditure, decreased insulin sensitivity, decreased muscle mass and
strength, and increased risk of disability (Fielding et al., 2011). More individuals are being
diagnosed with Sarcopenic-obesity before reaching the age of muscle degradation because of
sedentary lifestyle and malnutrition (Stenholm, Harris, Rantanen, Visser, Kritchevsky, &
Ferrucci, 2008).

History of Body Composition

The first study of body composition can date all the way back to 400 B.C. The ancient
Greeks first believed that people were made up of fire, water, air and earth (Heymsfield et al.,
2005). The benchmark of body composition occurred when Albert Behnke introduced
underwater weighing using Archimedes Principle and the two-component model in the 1940s
(Heymsfield et al., 2005). Archimedes Principle states, “a body immersed in a fluid is acted on
by a buoyancy force, which is evidenced by a “loss” of weight equal to the weight of the
displaced fluid,” (Heymsfield et al., 2005). The mathematical equation used to conduct
underwater weighing from Archimedes Principle is:
(1)
Db = ____________Wa____________
(Wa – Ww) - (RV + 0.100)
Dw
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The two-component model splits the body into two different compartments, fat (F) and
fat free mass (FFM) (Heymsfield et al., 2005). The fat component is made of all extractable
lipids in the body. The fat free mass component is made up of all water, proteins, and minerals in
the body. (Heyward & Stolarczyk, 1996). The two-component model is the “cornerstone” of
which hydrodensitometry is based (Heymsfield et al., 2005). There are two most common
equations for calculating body fat percentage based on the two-component model:
(2)
Siri: % fat = (4.95/Db – 4.50) x 100
(3)
Brozek: % fat = (4.570/Db – 4.142) x 100
In order for these equations to be accurate, there are assumptions that need to be understood. The
assumptions include: 1) Density of Fat is 0.901 gram per cubic centimeter, 2) Density of FFM is
1.103 gram per centimeter, 3) Density of both F and FFM are the same for everyone, and 4)
Individuals only differ in the amount of fat they have (Heyward & Stolarczyk, 1996). If these
assumptions are all met, two-component model equations can predict accurate estimates of body
fat percentage (Heyward & Stolarczyk, 1996). However, these assumptions are not always met
because FFM density differs between age groups, genders, ethnicities, levels of body fat
percentages and physical activity levels (Heyward & Stolarczyk, 1996). For example, African
Americans, children, and the elderly do not meet these assumptions. African American
individuals have a higher FFM density because they have higher mineral contents and more bone
density than the “reference model” assumptions. Children and elderly individuals have lower
FFM densities because they have lower mineral contents and bone densities than the “reference
model” (Heyward & Stolarczyk, 1996).
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Variations from subpopulations pushed researchers to further their understanding of the
components of the body. In 1961, a three-component model to measure total body fat values was
developed (Heymsfield et al., 2005). The three-component model consisted of body mass, body
volume, and total body water (TBW) (Heymsfield et al., 2005). A four-component model
consists of body volume, TBW, bone mineral, and body mass (Heymsfield et al., 2005). The
multi-component models reduce error rates from the assumptions needed for the two-component
model and when using the multi-component model equations, subpopulation assumptions are
also corrected for (Heymsfield et al., 2005). However, there are still assumptions that need to be
accounted for when using the multi-component models. These assumptions include: 1) Density
of water is 0.9937 g/cm3, 2) Density of bone mineral is 2.982 g/cm3, 3) Density of soft tissue is
3.317 g/cm3 and 4) Density of protein is 1.34 g/cm3.
Not long after W.E. Siri introduced the three-component model, the first bioelectrical
impedance analysis (BIA) method was introduced (Heymsfield et al., 2005). BIA methods use a
small electrical current to predict body fat percentages based on the resistance of current flow
through different components of the body such as TBW and FFM (Heyward & Stolarczyk,
1996). BIA systems assume that the various compartments of the body either act as conductors,
semiconductors, or insulators (Kushner, 1992). “Impedance is a function of resistance (R) and
capacitance (Xc) of the conducting substance, such that: Z2 = R2 + Xc2,” (Kushner, 1992). The
resistance is the opposition of flow of the alternating current and capacitance is the opposition to
flow from the electric current (Kushner, 1992). Thus, BIA systems function using multiple
mathematical equations using the difference impedance levels and frequencies based on specific
machines. There are four different types of bioelectrical impedance analyzers including the
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single-frequency BIA, multi-frequency BIA, segmental BIA, and segmental multi-frequency
BIA (Salmi, 2003).
Shortly after the introduction of BIA systems, in 1963, the dual-photon absorptiometry
(DPA) to measure body composition was developed (Heymsfield et al., 2005). DPA used
radioactive sources to measure body composition, which made it difficult to acquire very precise
measurements. Limitations of measuring body composition using DPA led to the development of
dual-energy X-ray absorptiometry (DXA) (Heymsfield et al., 2005). DXA uses X-ray technology
instead of radiation, which simplified the measurement of both soft tissue and bone content,
compared to the radioactive DPA. DXA scanners can measure bone mineral density (BMD), lean
tissue mass (LTM), fat mass (FM), soft tissue mass (STM), and fat free mass (FFM) (Heymsfield
et al., 2005). The Hologic DXA systems were the first manufactured in 1988 (Heymsfield et al.,
2005) and soon after the General Electric Lunar and General Electric Prodigy were manufactured
in the 1990’s (Heymsfield et al., 2005). Majority of research validation studies have used the GE
Lunar DXA machine.

Methods for Measuring Body Composition

There are two main ways that body composition is measured; circumference and body
density. The patterns in which fat is distributed affects the risk factors associated with obesity.
Central adiposity or “android” fat has a much higher risk for diabetes and CVD than lower body
obesity. Central adiposity is measured by waist to hip ratios and values above 0.8 for women and
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1.0 for men are categorized as increased health risk. Body composition via two-component
model can be measured using skinfold measurements, bioelectrical impedance analyzers or
anthropometric data such as circumference. Body composition via the multi-component model
can be measured using a DXA scanner, MRI, or CT.

Body Composition Devices

One common device used to measure body composition is the BIA. Both InBody 520 and
InBody S10 devices will be used for testing. A more uncommon device typically seen in medical
settings that will be used is the Hologic DXA scanner. Hologic DXA measures regional and
whole body bone mineral density, lean and fat tissue mass, calculates derivative values of: bone
mineral content, area, soft tissue mass, regional soft tissue mass, fat free mass, regional and total
soft tissue mass ratios, calculates percentages of regional body fat, total body fat, android fat,
gynoid fat, ratio of android to gynoid fat, and calculates body mass index (Hologic Horizon,
2015). These values are measured and calculated within the software and given on result print
outs. There are two X-ray beams at energies of 70 and 140 kVp that alternately pulse
continuously to create an image of the whole body. The scan occurs in a continuous series of
transverse scans that move from head to toe moving approximately 0.6 to 1.0 cm at a time,
making seven total passes over the body and takes approximately six minutes to complete
(Heymsfield, et al., 2005, Hologic Horizon, 2015). One complete whole body scan exposes the
subject to a maximal amount of radiation of 1.5 mrem; which is a very minimal amount of
radiation. For comparison, a flight in a commercial airplane across the continental United States
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has a radiation exposure of approximately four to six mrem and traditional X-rays can range
anywhere from 25 mrem up to 270 mrem (Heymsfield et al., 2005). The X-rays use assumed
constant attenuations of pure fat and bone mineral free lean tissue to calculate the different body
composition measurement values (Heymsfield et al., 2005). These assumptions are that pure fat
at X-ray energy of 40 kV and 70kV is 1.21 and that bone mineral free lean tissue is 1.399. The
software then calculates its needed values to create the results it produces.
As with any measurement tool, the DXA has both advantages and disadvantages to its
use. Some advantages to using a DXA include relatively quick results, multiple measurement
values, easy for subjects to “complete”, and it provides precise estimates of body composition
(Heymsfield et al., 2005). Disadvantages of using the DXA include no testing on pregnant
women, the equipment is expensive, training of technician for efficiency, and the accuracy
decreases in measuring large (>193 cm tall) or obese (wider than 58-65 cm or > 100kg)
individuals (Heymsfield et al., 2005).
Another measurement device for body composition is BIA. There is one underlying
principle of BIA systems: the relationship between body composition and water content of the
body (Heymsfield et al., 2005). BIA systems use a small alternating electrical current that enters
the body at a low and safe amperage (Heymsfield et al., 2005). Current flows through the body at
differing speeds based on the tissue that it is flowing through. Impedance from these analyzers
flows differently through intracellular water (ICW) and extracellular water (ECW) (Heymsfield
et al., 2005). The current will have less resistance when flowing through fat-free mass (FFM) and
more resistance when flowing through fat or bone (Heymsfield et al., 2005). The difference
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between these is based on the water content of the tissue. The more water, the less resistance the
current will encounter (Heymsfield et al., 2005).
BIA systems are either single or multi- frequency analyzers. The majority of the single
frequency analyzers operate at a frequency of 50 kHz but have different amperages (Heymsfield
et al., 2005). The InBody S10 omits an electrical frequency of 1, 5, 50, 250, 500, and 1000 kHz
throughout the duration of one test. The InBody 520 omits an electrical frequency of 5, 50, and
500 kHz throughout the duration of one test. “At this frequency, the impedance index is directly
related to the volume of total body water (TBW), but use of the impedance index to estimate
FFM and body fatness is based on the fraction of 73% of TBW in FFM (Heymsfield et al.,
2005). Hydration fraction of FFM is not constant among individuals or groups.,” (Heymsfield et
al., 2005).
Based on these differences, there are many different equations created for the use with
single frequency BIA systems based on criterion methods such as the DXA. The main difference
between single and multi-frequency BIA systems is that the single frequency BIA cannot
decipher between ICW and ECW but the multi-frequency BIA is able to. This difference makes
multi-frequency BIA systems more accurate in measuring interindividual differences in body
composition (Heymsfield et al., 2005).
Similar to other measurement devices, there are assumptions that need to be understood
when using BIA systems. These two assumptions include: 1) the body is shaped like a perfect
cylinder and has equal length and cross sectional area and 2) at a fixed frequency the impedance
to current through the body is directly related to the length and inversely related to the cross
sectional area (Heymsfield et al., 2005).
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The limitations that occur from BIA systems include the great variability based on food
and liquids consumed, hydration status, exercise, and menstrual cycle for females (Heymsfield et
al., 2005). In order for BIA systems to accurately estimate body composition, they must use
criterion tested regression equations from validated studies. Multiple research studies have been
done in order to assess the reliability and validity of BIA systems compared to DXA. However,
the majority of these studies have specifically used the General Electric (GE) LUNAR DXA.
Malavolti, Mussi, Poli, Fantuzzi, Salvioli, Battistini, and Bedogni (2003), conducted a study to
calibrate an eight-polar BIA against a DXA for body composition in healthy adults. They used
the InBody 3.0 and Lunar DRX-L DXA for three measurements (whole body, arm, and leg).
Their results indicated that the InBody 3.0 (Biospace Seoul, Korea) proved to be an accurate
method in measuring FFM and appendicular lean tissue mass (LTM) when compared to the GE
Lunar DXA (Malavolti, Mussi, Poli, Fantuzzi, Salvioli, Battistini, & Bedogni, 2003).
Ramel, Geirsdottir, Arnarson, and Thorsdottir (2011), conducted a study to compare FFM
estimates from regional handheld BIA, conventional BIA and DXA for Icelandic elderly
individuals. They used the Body Fat Monitor BF 306 for the handheld BIA, the Bodystat 1500
for the conventional BIA, and the Hologic QDR-2000 for the DXA measurements. The subjects
were measured once on all three devices, which were all done within a two-hour time period.
The results indicated that there was a high correlation between the two BIA systems and the
DXA but actual results varied by at least five kilograms of FFM.
Sillanpaa, Cheng, Hakkinen, Finni, Walker, Pesola, Ahtiainen, Stenroth, Selanne, and
Sipila (2014), conducted a study to measure the accuracy of direct segmental multi-frequency
BIA body composition values compared to their reference method DXA for Finnish men and
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women. They used the Lunar Prodigy DXA and InBody 720 eight polar multi-frequency BIA.
Measurements were taken after the subject had been fasting for 12 hours and between the hours
of 7 and 9am. The InBody 720 overestimated LM in both men and women and underestimated
FM and body fat percentage when compared to the DXA, however these differences were not
significant (p <.001) (Sillanpaa, Cheng, Hakkinen, Finni, Walker,…& Sipila, 2014).
Demura, Sato, and Kitabayashi (2004), conducted a study to compare the accuracy of
estimating body fat percentage from three BIA (TBF-101, BC-118, InBody 3.0) systems against
both a DXA and hydrostatic weighing (HW) as the reference model. The comparison testing
consisted of two trials of DXA and three BIA trials then one DXA and all BIA measurements on
one day then one more DXA scan on the following day in addition to 5 HW trials all taken on
their own day. The multi-frequency eight electrode BIA (InBody 3.0) had the highest correlation
to both the DXA and HW reference along with the lowest estimation of error (Demura, Sato, &
Kitabayashi, 2004).
Shafer, Siders, Johnson, and Lukaski (2009), conducted a study to determine if body fat
percentage, FM, and FFM were not significantly different between segmental multi-frequency
BIA and DXA among different body mass index (BMI) groups. Hologic DXA and the InBody
320 BIA were used for measurements. Only one measurement of each was collected. The
InBody 320 BIA overestimated segmental body fat percentage in both men and women by less
than one percent compared to DXA. Also, the multi-frequency BIA was better with those at
BMI’s of normal and overweight than with individuals that are obese (Shafer, Siders, Johnson, &
Lukaski, 2009).
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Obesity is an epidemic throughout not only the United States but most of the developed
world. Diseases such as T2DM, CVD, and hypertension can all be linked to obesity. Both the
measurement of fat mass and lean muscle mass contribute to distinguishing a person’s body
composition. Advances in technology have enabled health professionals to use machinery to
diagnose individuals as healthy, overweight, or obese. However, there are discrepancies between
the reliability and validity of the machinery compared to others, such as BIA systems compared
to DXA scanners. Based on variations of results between BIA and both the GE Lunar and
Hologic DXAs, it is important that more research be conducted to validate BIA measurements.
Thus, the purpose of this study is to validate the InBody S10 and InBody 520 against the Hologic
DXA System.
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CHAPTER 2

METHODOLOGY

Participants

Fifty male and female subjects were recruited via flyers posted around Northern Illinois
University campus in DeKalb, IL. Subjects were between the age of 18 and 29 years old (See
Table 1.0). The age range of 18 to 29 years was determined through the “young normal” data
provided on the Hologic DXA user manual, to keep the range consistent and matching.
Exclusion criteria for subjects was failure to pass a pregnancy test for females, age less than 18
or greater than 29 years old, contain any metal implants in body such as pins, staples,
pacemakers, etc., and being greater than 550 pounds. Any female subject that failed to pass a
pregnancy test would be excluded from participating due to the mild radiation from the DXA and
the electrical current from the InBody devices. Any subject that contained any metal implants
was excluded due to the fact that metal can skew results of the DXA and will incorrectly
interpret specific measurements. The maximal weight limit for the DXA scanner is 550 pounds;
therefore, any subject weighing more than 550 pounds was excluded from participation.
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Table 1.0
Subject Demographics
Variable

Males

Females

N
Weight (kg)
Height (cm)

31
87.8 ± 19.6
178.7 ± 6.6

19
63.9 ± 10.7
161.9 ± 7.1

Age (years)

23.1 ± 2.7

22.9 ± 2.0

Procedures

Participants were recruited to participate in the study via verbal proposal to Kinesiology
and Physical Education classes at Northern Illinois University and flyers posted in various
locations throughout the university campus (Appendix A). Upon interest in the study, subjects
scheduled a specific time to meet with the Principal Investigator (PI) of the study and completed
an informed consent (Appendix B) and an initial screening questionnaire (Appendix C). The
initial screening questionnaire asked the participant basic demographic values such as age,
gender, do they currently have any metal implants in their body or a pacemaker. The subjects
that met all inclusion criteria and qualified for participation in the study, then scheduled a time to
come back for testing (at least 24 hours later), and were instructed on proper guidelines to follow
for the day prior to and the day of testing to insure accurate results. At least 24 hours between
initial screening and testing was required for the subject to follow all of the pretest procedures.
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All subjects were given a document explaining what they are to refrain from 24 hours before and
instructions for the day of testing (Appendix E). All subjects refrained from eating for at least
five hours prior to testing but no more than 12 hours, did not exercise within eight hours prior to
testing, did not consume larger amounts of liquids within four hours prior to testing, did not
consume caffeine or other diuretics within three hours prior to testing, did not consume alcohol
within 12 hours prior to testing, and did not shower directly prior to testing. The subject was
asked to return for testing to the body composition lab at least 24 hours after the initial screening
meeting. Upon return for testing, the PI had a questionnaire that the subject answered truthfully
to ensure they followed all pretesting guidelines (Appendix D). When the subject returned for
testing, if female, they immediately were given a pregnancy test to confirm participation in the
study. When the pregnancy test came back negative or if the subject is male, the PI then
confirmed with the subject that they have followed all pretesting procedures from the Pretest
Guidelines form. Once confirmed, the subject (if male) was asked to void all contents of their
bladder, females already having done so during pregnancy test. Upon return from the restroom,
they were given a hospital gown to change into and removed all clothing excluding underwear
(unless it contains any type of metal) and jewelry of any kind. The subject was then asked again
to ensure they were not wearing any metal including removable piercings or jewelry. Height was
then measured to the nearest centimeter using a wall mounted stadiometer and weight was
measured to the nearest tenth of a kilogram once on the InBody 520.
The subject stood for 15 minutes prior to beginning the InBody 520 due to proper
hemodynamics of blood flow. Standing for 15 minutes prior to the InBody 520 is crucial because
the InBody 520 recognizes that the subject is in the standing position and time needs to be
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allotted for all blood and body fluids to properly circulate/pool to where they typically would be
while standing due to gravity (Klabunde, 2005). Gravity acts upon the bodies venous return
system causing blood to accumulate in the lower extremities (Klabunde, 2005). The subject was
then asked to wipe their hands and feet with the InBody tissue provided before stepping onto the
foot electrodes with heels properly on the heel electrodes and feet rolled forward for proper foot
placement. Once the InBody 520 recognizes and confirms the subject’s body weight, the
subject’s personal data was inputted including height, gender, age, and study identification
number. Once all data was entered properly, the subject was asked to grab hold of the hand
electrodes, making sure that their thumbs were in proper placement over the electrodes. The
subject was instructed to have arms straight and away from the body at approximately at 40degree angle and stand upright with good posture. The subject was then instructed to stand still
for the duration of the test, which took approximately 90 seconds to complete. Once the test was
complete, the subject was instructed to step off the machine.
Once the InBody 520 was completed, the subject was asked to lay supine on the DXA
bed for 15 minutes. Lying in the supine position for 15 minutes was crucial for the InBody S10
because the InBody S10 recognizes that the subject was in the lying supine position. Therefore,
when someone is lying down, their blood and fluid pools differently than while standing because
gravity is not acting upon their body (Klabunde, 2005). Following the 15 minutes, the subject
was prepped for the InBody S10. One electrode was attached to each ankle and one electrode
was attached to each thumb and middle finger for a total of six electrodes. Once the electrodes
were in place, the PI started the S10 to collect measurements. The subject was instructed to
remain as still as possible through the duration of the test, which took approximately 90 seconds
to complete.
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After completion of the InBody S10, prior to beginning the DXA scan, the PI entered
data into the DXA computer specific to the subject such as their identification number, age,
height, and weight. All of this information was already filled out on their Initial Screening
Questionnaire and the InBody 520 already measured their body weight. The subject was then
placed within the scanning rectangle on the DXA bed by the PI, with proper arm placement,
positioned at the subject’s side and slightly pronated with their fingers pointed straight. The
subject’s toes were also pointed up and their feet were held together by a plastic strap to
eliminate movement throughout the scan. Once the subject was in position, the subject was
instructed to remain as still as possible for the duration of the scan. The whole body scan took
just over 6 minutes to complete.
Following the completion of the first test on all three devices, the subject was retested on
the InBody S10 and the InBody 520. Only one DXA scan was needed because the same scan was
analyzed twice. The retest procedures were identical to the initial test. The values collected
included total body fat percentage, appendicular lean mass, appendicular fat mass, trunk
adiposity, visceral fat, total lean mass, and total fat mass, intracellular water weight, extracellular
water weight, total body water, and skeletal muscle mass.
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Figure 1.0: Study Design Flow Chart

Statistical Analysis

JMP Statistical Discovery Software from SAS Version 12.2.0 (Cary, NC) was used to run
a matched pairs T test and one-way analysis of variance (ANOVA) statistical analysis on all data
collected for the InBody 520, InBody S10 and Hologic DXA. The significance level was set as p

24
<.05 with a confidence interval of 95%. A Tukey post-hoc test was also used to analyze specific
variables.
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Chapter 3

RESULTS

After analyzing the three devices, the variables will be grouped into three categories
including: standard body composition measurements of percent body fat, lean body mass (kg)
and body fat mass (kg), segmental lean tissue (kg) measurement of right arm, left arm, right leg,
left leg, and trunk, and miscellaneous measures such as visceral adipose tissue (cm2),
intracellular water (kg), extracellular water (kg), total body water (kg), and skeletal muscle mass
(kg). Test/retest reliability of the DXA was established by having two trained clinicians analyze
the first 10 scans twice (for a total of four analyses) for reliability. The average of the first ten
scan analyses from analyst one are represented by analysis reading A and the average of the
second ten scan analyses from analyst two are represented by analysis reading B. The test/retest
reliability was established by both comparing the additional trained analyst to themselves for
analysis reading A compared to analysis reading B and also by comparing the additional analysts
reading A and B to the Principal Investigator’s analysis reading A and B. The remaining 41
subjects were scanned once and analyzed twice by the Principal Investigator, for Trial A and B
results. Therefore, all variables were then analyzed from Trial A to Trial B for the same device,
then by variable between devices, and lastly by variable based on gender. Trial A was the first
time that the subject was tested using each device. Trial B was the second time each subject was
tested on each device. Trial A and Trial B were done on the same day.
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There was no statistical significant difference between analysis reading A (29.70 ± 6.60)
to analysis reading B (29.53 ± 6.41) for percent body fat for the second DXA analyst, p=.2745.
There was no statistical significant difference between analysis reading A (56.07 ± 13.05) to
analysis reading B (56.18 ± 12.93) for total lean body mass, p=.3189. There was no statistical
significant difference between analysis reading A (23.21 ± 4.85) to analysis reading B (23.11 ±
4.78) for total body fat mass, p=.3214. There was no statistical significant difference between
analysis reading A (3.86 ± 1.40) to analysis reading B (3.89 ± 1.36) for right arm lean tissue,
p=.4886. There was no statistical significant difference between analysis reading A (3.69 ± 1.40)
to analysis reading B (3.77 ± 1.39) for left arm lean tissue, p=.2166. There was no statistical
significant difference between analysis reading A (9.13 ± 2.18) to analysis reading B (9.06 ±
2.10) for right leg lean tissue, p=.2189. There was no statistical significant difference between
analysis reading A (7.98 ± 3.23) to analysis reading B (8.86 ± 2.16) for left leg lean tissue,
p=.4015. There was no statistical significant difference between analysis reading A (24.79 ±
8.51) to analysis reading B (26.93 ± 5.71) for trunk lean tissue, p=.2945. There was also no
statistical difference between analysis reading A (74.05 ± 20.82) to analysis reading B (74.60 ±
21.47) for visceral adipose tissue for the additional DXA analyst, p=.5063.
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Table 2.0
Test/Retest Reliability Matched Pairs T Test

Percent Body Fat
Total Lean Body Mass
Total Body Fat Mass
Right Arm Lean Tissue
Left Arm Lean Tissue
Right Leg Lean Tissue
Left Leg Lean Tissue
Trunk Lean Tissue
VAT

Analysis
Reading A
29.70 ± 6.60
56.07 ± 13.05
23.21 ± 4.85
3.86 ± 1.40
3.69 ± 1.40
9.13 ± 2.18
7.98 ± 3.23
24.79 ± 8.51
74.05 ± 20.82

Analysis
Reading B
29.53 ± 6.41
56.18 ± 12.93
23.11 ± 4.78
3.89 ± 1.36
3.77 ± 1.39
9.06 ± 2.10
8.86 ± 2.16
26.93 ± 5.71
74.60 ± 21.47

There was no significant differences between the two investigators DXA analyses when
measuring percent body fat, total lean body mass, total body fat mass, right arm lean tissue, left
arm lean tissue, left leg lean tissue, trunk lean tissue, or visceral adipose tissue (refer to Table
3.0). However, there was a significant difference between the two analyses of the same DXA
scan when measuring right leg lean tissue for analysis reading A (p=.0071).
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Table 3.0
Test/Retest Reliability Matched Pairs T Test: Analysis
Reading A
Analysis
Analysis
Reading AReading APrincipal
Additional
Investigator
Analyst
Percent Body Fat
29.58 ± 6.47
29.7 ± 6.60
Total Lean Body Mass
56.14 ± 12.9 56.07 ± 13.05
Total Body Fat Mass
23.05 ± 4.84
23.21 ± 4.85
Right Arm Lean Tissue
3.77 ± 1.39
3.86 ± 1.40
Left Arm Lean Tissue
3.65 ± 1.34
3.69 ± 1.33
Right Leg Lean Tissue
9.38 ± 2.23
9.13 ± 2.18*
Left Leg Lean Tissue
9.31 ± 2.19
7.98 ± 3.22
Trunk Lean Tissue
23.33 ± 8.56
24.79 ± 8.51
VAT
74.81 ± 21.52 74.05 ± 20.82
*=p=.0071; A

B

There was no statistical significant differences for analysis reading B between the
Principal Investigator and the additional analyst when measuring percent body fat, total lean
body mass, total body fat mass, right arm lean tissue, left arm lean tissue, right leg lean tissue,
left leg lean tissue, or trunk lean tissue (refer to Table 4.0). There was statistical significance for
analysis reading B between the Principal Investigator and the additional analyst when measuring
visceral adipose tissue (p=.0467).
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Table 4.0
Test/Retest Reliability Matched Pairs T Test: Analysis
Reading B
Analysis
Analysis
Reading BReading BPrincipal
Additional
Investigator
Analyst
Percent Body Fat
29.61 ± 6.42
29.53 ± 6.41
Total Lean Body Mass
51.61 ± 21.91
56.18 ± 12.93
Total Body Fat Mass
23.17 ± 4.87
23.11 ± 4.78
Right Arm Lean Tissue
3.82 ± 1.43
3.89 ± 1.36
Left Arm Lean Tissue
3.20 ± 1.70
3.77 ± 1.39
Right Leg Lean Tissue
8.67 ± 3.76
9.10 ± 2.10
Left Leg Lean Tissue
8.23 ± 3.63
8.86 ± 21.56
Trunk Lean Tissue
26.31 ± 5.37
26.93 ± 5.71
VAT
74.91 ± 21.49 74.60 ± 21.47*
*=p=.0467; A

B

The standard body composition measurements consist of percent body fat, lean body
mass (kg), and body fat mass (kg). There was a statistical significance difference between Trial
A (20.2 ±9.7) and Trial B (20.5 ± 9.5) for the InBody 520 for the variable percent body fat,
p=.02. There was a statistical significance between Trial A (62.3 ± 15.1) and Trial B (62.1 ±
15.2) for the InBody 520 for lean body mass, p=.02. There was no statistical significant
difference between Trial A and Trial B for the InBody 520 for body fat mass, p=.10.
There were no statistical differences seen for the three variables for the DXA between
Trial A and Trial B for percent body fat (p=.23), lean body mass (p=.94), and body fat mass
(p=.30) (refer to Table 2.0). There were also no statistical differences between Trial A and Trial
B for the InBody S10 between percent body fat (p=.26), lean body mass (p=.53), and body fat
mass (p=.08) (refer to Table 2).
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Table 5.0
Body Composition Measures Matched Pairs T Test Analysis

Body Fat
Percentag
e
Lean
Body
Mass
Body Fat
Mass

InBody
520
Trial A
20.2 ± 9.7

InBody 520
Trial B

DXA
Trial A

DXA
Trial B

20.5 ± 9.5*

28.9 ± 8.2

62.3 ± 15.1

62.1 ±
15.2*

16.4 ± 10.6

16.6 ± 10.6

*=p<.03; A

28.9 ± 8.2

InBody
S10
Trial A
21.9 ± 9.9

InBody
S10
Trial B
21.8 ± 9.8

54.7 ±
14.3

54.7 ±
14.4

61.1 ±
15.3

60.8 ±
16.0

22.3 ± 9.4

22.3 ± 9.4

18.0 ±
11.0

17.9 ±
10.8

B

There were statistically significant differences between at least two of the devices for all
three of the standard body composition measurements including percent body fat, lean body
mass, and body fat mass. Percent body fat was significantly greater for the DXA (28.9 ± 8.2)
than the InBody 520 (20.4 ± 9.6) and the DXA was also significantly greater than the InBody
S10 (21.8 ± 9.8); p<.001 and p=.006, respectively. Lean body mass values were significantly
less on the DXA (54.7 ± 14.4) compared the InBody 520 (62.2 ± 15.1), p=.04. While not
significant, the InBody S10 lean body mass (61.0 ± 15.6) was greater than the DXA. Body fat
mass values were significantly greater on the DXA (22.3 ± 9.4) compared to the InBody 520
(16.5 ± 10.6), p=.02. While not significant, the InBody S10 body fat mass (17.9 ± 10.9) values
were less than the DXA.
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Table 6.0
Body Composition Variables One-Way ANOVA Analysis

Body Fat
Percentage
Lean Body
Mass
Body Fat
Mass

InBody 520

DXA

InBody
S10

Significance

20.4 ± 9.6

28.9 ± 8.2*

21.8 ± 9.8

* = p<.001; DXA > 520 = S10

62.2 ± 15.1

54.7 ± 14.4*

61.0 ± 15.6

* = p<.04; DXA < 520 = S10

16.5 ± 10.6

22.3 ± 9.4*

17.9 ± 10.9

* = p<.02; DXA > 520 = S10

The segmental lean tissue data will consist of right arm lean tissue, left arm lean tissue,
right leg lean tissue, left leg lean tissue, and trunk lean tissue. There was no statistically
significant differences between Trial A and Trial B for the right arm lean tissue between the
InBody 520 (3.66 ± 1.16, 3.67 ± 1.20, p=.1389) or the DXA (3.57 ± 1.31, 3.58 ± 1.34, p=.0687).
However, there was a statistically significant different between Trial A (3.55 ±1.15) and Trial B
(3.58 ± 1.16) for right arm lean tissue on the InBody S10, p<.0001. There was no statistically
significant differences between Trial A and Trial B for the left arm lean tissue between the
InBody 520 (3.63 ± 1.16, 3.63 + 1.19, p=.5481) or the DXA (3.43 ± 1.31, 3.44 ± 1.32, p=.5245).
There was a statistically significant different between Trial A (3.61 ± 1.44) and Trial B (3.64 ±
1.46) for left arm lean tissue on the InBody S10, p=.0006.
There was no statistically significant differences between Trial A (9.03 ± 2.49) and Trial
B (9.07 ± 2.52) for the right leg lean tissue for the DXA, p=.0592. There was statistically
significant difference between Trial A (9.22 ± 2.07) and Trial B (9.12 ± 2.06) for right leg lean
tissue on the InBody 520, p<.0001. There was also a statistically significant difference between
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Trial A (9.25 ± 2.22) and Trial B (9.19 ± 2.23) on the S10 for right leg lean tissue, p=.002. There
was no statistically significant differences between Trial A (8.91 ± 2.42) and Trial B (8.96 ±
2.46) for the left leg lean tissue for the DXA, p=.0855. There was a statistically significant
difference between Trial A (9.17 ± 2.05) and Trial B (9.08 ± 2.06) for the left leg lean tissue on
the InBody 520, p<.0001. There was also a statistically significant difference between Trial A
(9.21 ± 2.19) and Trial B (9.15 ± 2.19) on the S10 for right leg lean tissue, p=.0001. However,
there was no statistical significant difference between Trial A (28.05 ± 6.73) and Trial B (28.07
± 6.95) for trunk lean tissue on the InBody 520, p=.7739. There was statistically significant
differences between Trial A (26.13 ± 6.62) and Trial B (26.03 ± 6.58) on the DXA, p=.02; and
between Trial A (27.41 ± 6.71) and Trial B (27.57 ± 6.77) on the InBody S10, p<.001.

Table 7.0
Segmental Lean Tissue Matched Pairs T Test Analysis

Right Arm
Left Arm
Right Leg
Left Leg
Trunk

InBody 520
Trial A
3.66 ± 1.16
3.63 ± 1.16
9.22 ± 2.07
9.17 ± 2.05
28.05 ± 6.73
*=p<.02; A

InBody 520
Trial B
3.67 ± 1.20
3.63 ± 1.19
9.12 ± 2.06*
9.08 ± 2.06*
28.07 ± 6.95

DXA
Trial A
3.57 ± 1.31
3.43 ± 1.31
9.03 ± 2.49
8.91 ± 2.42
26.13 ± 6.62

DXA
Trial B
3.58 ± 1.34
3.44 ± 1.32
9.07 ± 2.52
8.96 ± 2.46
26.03 ± 6.58*

InBody S10
Trial A
3.55 ± 1.15
3.61 ± 1.44
9.25 ± 2.22
9.21 ± 2.19
27.41 ± 6.71

InBody S10
Trial B
3.58 ± 1.16*
3.64 ± 1.46*
9.19 ± 2.23*
9.15 ± 2.19*
27.57 ± 6.77*

B
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For right arm lean tissue, there was no statistical significance difference between the
InBody 520 and the InBody S10, p=.9043, between the InBody 520 and the DXA, p=.9278, or
between the DXA and the InBody S10, p=.9981. For left arm lean tissue, there was no statistical
significance difference between the InBody 520 and the InBody S10, p=.8891, between the
InBody 520 and the DXA, p=.7088, or between the DXA and the InBody S10, p=.9419. For the

right leg lean tissue, there was no statistical significance difference between the InBody 520 and
the InBody S10, p=.9930, between the InBody 520 and the DXA, p=.9626, or between the DXA
and the InBody S10, p=.9251. For the left leg lean tissue, there was no statistical significance
difference between the InBody 520 and the InBody S10, p=.9925, between the InBody 520 and
the DXA, p=.9048, or between the DXA and the InBody S10, p=.8502. For the trunk lean tissue,
there was no statistical significance difference between the InBody 520 and the InBody S10,
p=.9055, between the InBody 520 and the DXA, p=.3067, or between the DXA and the InBody
S10, p=.5474.
Table 8.0
Segmental Lean Tissue One-Way ANOVA Analysis

Right Arm
Left Arm
Right Leg
Left Leg
Trunk

InBody 520

DXA

InBody
S10

3.7 ± 1.2
3.6 + 1.2
9.2 ± 2.1
9.1 ± 2.1
28.1 ± 6.8

3.6 ± 1.3
3.4 ± 1.3
9.0 ± 2.5
8.9 ± 2.4
26.1 ± 6.6

3.6 ± 1.2
3.5 ± 1.1
9.2 ± 2.2
9.2 ± 2.2
27.5 ± 6.7
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The remaining variables; visceral adipose tissue (VAT) (cm ), intracellular water (ICW)
2

(kg), extracellular water (ECW) (kg), total body water (TBW) (kg), and skeletal muscle mass
(SMM) (kg). There was no statistical significance differences found between Trial A (71.2 ±
37.8) and Trial B (71.3 ± 37.7) for VAT on the DXA, p=.3989 or between Trial A (74.2 ± 51.9)
and Trial B (73.5 ± 51.2) on the InBody S10, p=.2624. VAT was not measured on InBody 520.
There was statistical significant difference between Trial A (28.9 ± 7.1) and Trial B (28.7 ± 7.1)
for ICW on the InBody 520, p=0.04. There was no statistical difference between Trial A (29.1 ±
10.1) and Trial B (29.2 ± 10.0) for ICW on the InBody S10, p=.3982. There was a statistical
significant difference between Trial A (16.8 ± 4.0) and Trial B (16.7 ± 4.1) for ECW on the
InBody 520, p=.005. There was no statistical difference between Trial A (17.0 ± 5.7) and Trial B
(16.8 ± 5.8) for ECW on the InBody S10, p=.2550. However, there was a statistical significant
difference between Trial A (45.7 ± 11.1) and Trial B (45.5 ± 11.1) for TBW on the InBody 520,
p=.02. There was no statistical difference between Trial A (46.1 ± 15.7) and Trial B (46.2 ±
15.7) for TBW on the InBody S10, p=.6535. ICW, ECW, and TBW were not measured on DXA.
There was no statistical difference between Trial A (34.7 ± 9.4) and Trial B (35.0 ± 9.4) for
SMM on InBody S10, p=.0584. SMM was not measured on DXA or InBody 520.
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Table 9.0
Miscellaneous Measures Matched Pairs T Test Analysis
InBody 520
InBody
Trial A
520 Trial B
VAT
ICW

28.9 ± 7.1

28.7 ± 7.1*

ECW
TBW

16.8 ± 4.0
45.7 ± 11.1

16.7 ± 4.1*
45.5 ±
11.1*

SMM
*=p<.05; A

DXA
Trial A

DXA
Trial B

71.2 ±
37.8

71.3 ±
37.7

InBody
S10
Trial A
74.2 ±
51.9
29.1 ±
10.1
17.0 ± 5.7
46.1 ±
15.7
34.7 ± 9.4

InBody
S10
Trial B
73.5 ±
51.2
29.2 ±
10.0
16.8 ± 5.8
46.2 ±
15.7
35.0 ± 9.4

B

Through post hoc analysis, the data was divided by gender. Matched pairs t-test were
used to analyze all variables based on gender. First, looking at the standard body composition
variables, there was only statistical significance for percent body fat between Trial A and Trial B
for the three devices, p=.0284 for females. For the segmental lean tissue variables, there was
significance across the board. Right arm and left arm lean tissue Trial A to Trial B was
significantly different for males, p<.001 and p=.0097 respectively. Right and left leg lean tissue
was statistically significant for females, p=.0028 and p=.0115, respectively.
Right leg lean tissue in the males was statistically different between Trial A and Trial B,
p=.0386. Between Trial A to Trial B, there was a statistical significant difference for females in
ECW, p=.0071, but not in the males, p=.3266. Skeletal muscle mass was statistically different
for males between Trial A and Trial B, p=.0162, but not in the females, p=.2899.
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Figure 2: Mean Percent Body Fat Differences Between Devices Used for 50 Male and Female
Subjects
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Figure 3: Mean Lean Body Mass (kg) Differences Between Devices Used for 50 Male and
Female Subjects
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Figure 4: Mean Body Fat Mass (kg) Differences Between Devices Used for 50 Male and Female
Subjects
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Chapter 4

DISCUSSION

Obesity is a growing epidemic in the United States and various countries around the
world (Ehrman et al., 2013); therefore, valid and reliable measures of body composition are
important. Obesity, determined by body mass index (BMI) and body fat percentage, have been
well established as an independent risk factor for multiple diseases such as cardiovascular
disease (CVD), Type 2 diabetes mellitus (T2DM), and hypertension (Ogden et al., 2014).
Discovering new and improved methods for measuring body fat percentage is crucial for the
current obesity problem. Therefore, the purpose of this study was to validate the InBody S10 and
InBody 520 against the Hologic DXA System.
The two InBody systems, the 520 and the S10, were more closely related in determining
body fat percentage when compared to the dual energy X-ray absorptiometry (DXA). Therefore,
for Trial A and for Trial B the InBody 520 and InBody S10 had similar values when compared to
the DXA values for percent body fat. The DXA was significantly higher (p<.001) when
measuring body fat percentage compared to the InBody 520 and compared to the InBody S10
(refer to Table 6.0). The difference in body fat could be attributed to that the two InBody devices
are multi-frequency bioelectrical impedance analyzers (BIA). Multi-frequency BIAs have eight
electrodes and have the ability to use the ratio between the high and low frequencies to
accurately measure body composition through body water estimation of individuals in the
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normal, obese, and lean categories (Demura, Sato, & Kitabayashi, 2004). Whereas the DXA
simply relies on the X-ray image and personal investigator analysis skill for determining body fat
percentage regardless of the individuals build. Thus, the mechanical differences between the
machines could account for the body fat difference between the two InBody devices and the
DXA. There was no statistical difference (p=.7097) in measuring body fat percentage between
the InBody 520 and InBody S10.
According to Salmi (2003), two main factors play a huge part in body composition
measurements for these specific devices, hydration and body fat. Hydration status has the ability
to greatly affect not only the BIA systems but also the DXA. Specifically, for the DXA,
hydration status will affect the estimation of fat free mass (FFM). When estimating body
composition on the BIA devices, hydration status will affect the intracellular water (ICW),
extracellular water (ECW), and total body water (TBW) content which will then affect the
estimation of body fat percentage (Salmi, 2003). Therefore, if any of the subjects were not
truthful in following the pretest guidelines of not consuming large amounts of liquids for four
hours prior to testing, their body fat percentage could be skewed. Also, based on the mechanical
functioning of the BIA, hydration status could be responsible for the greater difference between
the DXA and the InBody 520 and InBody S10.
Body fat content also has an impact on measuring body composition in these devices.
The largest cause of error comes from individuals that are very lean or very obese (Salmi, 2003).
Errors of body composition due to these extremes stem from the fact that the equations used for
these devices were created based on individuals of average body composition (Salmi, 2003). The
two of these factors, hydration and body fat, combine for greater error for individuals in the very
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lean or very obese categories because those individuals also tend to have much different tissue
hydration compared to those average individuals (Salmi, 2003).
The data was then further analyzed by gender between Trial A and Trial B for percent
body fat. There was a significant difference between Trial A and Trial B for female percent body
fat (p=.0284) but not for male (p=.8221). For females, Trial B was significantly higher than Trial
A. Significantly different body fat measures from Trial A to Trial B for females only could be
attributed to a difference in genetic make up because females on average tend to have higher
body fat compared to males.
Another explanation for the differences in genders between Trial A and Trial B could be
related to the time allotted for standing and lying down prior to each InBody measurement. There
is a slight possibility that females require more time for their blood to return to its natural state
based on the position because they have smaller cardiac outputs than males (Klabunde, 2005).
Therefore, blood and fluid pooling could affect the amount of fluids in the tissues from Trial A to
Trial B.
The results of this study indicate the only significant difference for lean body mass for a
specific device, was between Trial A and Trial B for the InBody 520 (p<.03). The difference
between the two trials could be attributed to the amount of standing time before each trial.
During the first 15 minutes of standing before Trial A, the subject was walking back from the
rest room and changing into the hospital gown whereas for the 15 minutes of standing prior to
the second trial, the subject was strictly standing and not walking more than a couple steps at a
time in a small area. A significant difference was only found when measuring lean body mass
between the DXA and the InBody 520 (p<.0362) (refer to Table 7.0). Other researchers, Shafer,
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Siders, Johnson, and Lukaski (2009), also indicated differences between BIA and DXA, as seen
in our study (Shafer et al., 2009), which indicated that lean body mass was overestimated in the
BIA device used (InBody 320) when compared to the DXA (Hologic QDR DELPHI-W) for
males but not females, and in both the normal and overweight BMI categories. Also, Shafer and
colleagues (2009) discovered that waist circumference of their subjects explained 36% of their
prediction error for the multi-frequency BIA percent body fat values. The amount of error that
comes from trunk estimations supports the suggestion that some BIA devices cannot accurately
measure the composition of the trunk segment, especially in individuals that are considered
obese (Shafer et al., 2009). Therefore, a difference between the InBody 520 and the DXA in
measuring lean body mass could also be attributed to differing levels of trunk adiposity among
subjects. The difference between the InBody 520 and DXA when measuring lean body mass
could be in part due to the InBody 520 impedance error or due to the analysis of the DXA scan
by the Principal Investigator. Placement of the visceral adipose tissue section can easily be
skewed if one marker is placed even .001cm different.
However, the accuracy of the Principal Investigator was checked with similar analysis of
ten DXA scans with another certified DXA analyst. A Pearson correlation coefficient was used
to analyze three different aspects of each scan including total body fat percentage, total fat mass,
and total lean mass. The Pearson correlation coefficient for total body fat percentage was .9982,
.9963 for total fat mass, and .9995 for total lean mass. Therefore, all three correlation coefficients
express a very strong correlation (Evans, 1996) limiting the amount of error from having one
DXA scan.
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There was no significant difference between the DXA and the InBody S10 (p=.0961) or
between the InBody 520 and InBody S10 (p=.9117). This difference between only the DXA and
the InBody 520 and not between the DXA and the InBody S10 could be impart due to the
impedance levels of the InBody S10. The highest level of impedance from the InBody S10
doubles that of the InBody 520; therefore, the InBody S10 may be slightly more accurate in
measuring lean body mass compared to the InBody 520. Lean body mass was not significantly
different for males (p=.6758) or females (p=.1773) between Trial A and Trial B.
The DXA was significantly higher in measuring body fat mass compared to the InBody
520 (p=.0156). According to Ramel, Geirsdottir, Arnarson, and Thorsdottir (2011), BIA
underestimated body fat mass in both male (6.3 points) and females (2.3 points). Considering
there are different calibers of BIA devices, the InBody 520 may be more likely to underestimate
body fat mass compared to the InBody S10, which could account for the body fat mass
difference between only the DXA and the InBody 520 and not the InBody S10. The InBody S10
has a greater level of impedance, which likely lowered the rate of error when compared to the
InBody 520 in measuring body fat mass.
The DXA measured body fat percentage and body fat mass greater than the InBody 520
and the InBody S10, which is expressed in the image below, Figure 5.0, which is an image of a
lean subject used in this study. The DXA measured his body fat percentage as 22.2% where as
the InBody 520 measured his body fat percentage as 6.7% and the InBody S10 measured his
body fat percentage as 8.7%. It is very noticeable that this individual is closer to the 7-8% body
fat percentage, rather than 22%. The DXA measured his body fat mass as 13.4 kg whereas the
InBody 520 measured his body fat mass as 4.1 kg and the InBody S10 measured his body fat
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mass as 5.4 kg. Thus, the potential error lies with the DXA itself, specifically when measuring
lean individuals, and not due to the Principal Investigator’s analysis accuracy due to the testretest reliability as discussed above. Therefore, the DXA is overestimating body fat percentage
and body fat mass, specifically in lean individuals specifically.

Figure 5.0: Lean Subject Body Image
There was no significant difference between the DXA and the InBody S10 (p=.0909) or
between the InBody 520 and InBody S10 (p=.7672) for body fat mass. The difference between
the DXA and the InBody devices indicate that the InBody S10 lies between the DXA and
InBody 520 in terms of comparison because the InBody 520 and InBody S10 are not
significantly different nor are the InBody S10 and the DXA, but the DXA and InBody 520 are
significantly different in measuring body fat mass. This difference between the three difference
devices may also be attributed to the difference in the impedance levels of the InBody’s such as
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with what may have caused the difference in measuring lean body mass. Body fat mass was not
significantly different for either gender between Trial A and Trial B (p=.6758).
There were limitations to this study, the first being the personal investigator had to rely
on honesty of subjects for subject compliance and adherence to all pretest guidelines. There was
no actual way of determining if the subjects were truthful or not when answering the pretest
guidelines checklist. Second, there was only one criterion device used, the DXA. Using another
criterion method such as hydrostatic weighing or BodPod could have given more insight to if the
InBody machines were more accurate than the DXA or vice versa. Therefore, future research for
validating the InBody 520 and InBody S10 against the Hologic DXA should include another
criterion method for testing. Also, recruiting based on BMI or by body fat percentage may
provide greater insight into if the InBody devices or the DXA are more accurate with specific
body composition make-ups.
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Appendix A

Validity of Whole and Regional Body Composition
Testing Devices
Are You Interested In Body Composition?
Are you a male or female within the ages of 18 to 29 years old
without any metal implants?
Participation in this study may be just for you!
Participants will be tested on InBody 520, InBody S10, and DXA
Approximately 1.5 hours of your time will be required over 2 visits
*** DXA scan does expose participant to minimal amounts of
radiation***
**Negative pregnancy verified by test will be required for females**
For more information, please contact:
Alexa Suida (a graduate student in the department of KNPE at NIU):
asuida1@niu.edu
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Appendix B
Recruitment Speech for KNPE Classes
Hello,

My name is Alexa Suida and I am a graduate student in the KNPE Exercise Physiology program
here at Northern Illinois University. I am currently recruiting both males and females within the
ages of 18 and 29 years old to participate in my thesis titled “Validity of Whole and Regional
Body Composition Testing Devices”. The study will take place over two meetings with the
Principal Investigator and will take approximately one and a half hours of your time. The first
meeting will be to go over the process of testing, informed consent, and initial screening to check
for eligibility in the study. Inclusion criteria for this study are being within 18 and 29 years old,
females must be able to pass negative pregnancy test day of testing, must not have any metal
implants, and weigh less than 550 pounds. Testing will consist of two Bioelectrical Impedance
Analysis(BIA) devices and a Dual Energy X-Ray Absorptiometry(DXA) scanner. The DXA scan
does emit minimal amounts of radiation and each subject will only be scanned once. The subject
will be tested twice on both BIA devices. If you are interested in participating in this study or
would like any further information, please contact me at asuida1@niu.edu.

Thank you for your time!
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54
APPENDIX C

Department of Kinesiology and Physical Education
Informed-Consent Form to Act as a Participant in a
Research Study

Title: Validity of Whole and Regional Body Composition Testing Devices
I agree to participate in the research project titled “Validity of Whole and Regional Body
Composition Testing Devices” being conducted by Alexa Suida, a graduate student in the
department of Kinesiology and Physical Education at Northern Illinois University. I have been
informed that the purpose of this investigation is to compare body composition measurements
such as total body fat percentage, appendicular lean mass, appendicular fat mass, trunk adiposity,
visceral fat, total lean mass, and total fat mass taken from InBody 520TM, InBody S10TM and
Hologic Horizon Dual Energy X-ray (DXA) scanner.
I understand that I am eligible for this study because I am within the ages of 18 and 29, if female,
I can verify negative pregnancy by taking a pregnancy test on the day of testing, I have no metal
implants, and I am less than 550 pounds.
I understand that if I agree to participate in this investigation and I am eligible to participate, I
will be asked to do the following: 1) complete an informed consent form, 2) complete an initial
screening questionnaire prior to any participation, 3) allow the Principal Investigator to evaluate
my height, weight, and body composition via InBody 520TM, InBody S10TM, and DXA.
I understand that my participation will be over the course of 2 days, the first day will consist of
the initial screening questionnaire, informed consent, and explanation of guidelines to follow for
testing, and the second day will consist of all testing including the InBody 520TM, InBody S10TM,
DXA, InBody S10TM, and InBody 520TM. I am aware that I will be tested twice on the two BIA
systems but only once on the DXA. I am aware that I will be given a specific time to arrive at the
Advanced Testing Laboratory in Anderson Hall. The total time of my participation will last
approximately 60 minutes. I understand what is involved with my participation in the experiment
as explained verbally to me by the Principal Investigator.
I am aware that my participation is voluntary and I may withdraw at any time without penalty or
prejudice. I understand that if I have additional questions or concerns regarding this project, I
may contact Alexa Suida (586-216-8320). I am aware that if I have further concerns or need
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more information regarding my rights as a research participant, I may contact the Office of
Research Compliance at Northern Illinois University at (815) 753-8588.
I understand there are foreseeable risks to me if I agree to participate in the study, including any
adverse effects caused by exposure to radiation.
A DXA is a type of X-ray used to measure bone strength and content, as well as body
composition. During the DXA test, X-rays of your body will be taken to measure how much
body fat and lean muscle tissue (non-fat tissue) are present. I will be lying flat on a table during
the test, while the machine takes pictures of different areas of the body. The test itself will last
approximately 6 minutes; however, I will be lying down for a total of 15 minutes while I am
positioned for the test.
A bioelectrical impedance analyzer is a device that uses a small electrical current to predict body
fat percentages based on the resistance of current flow through different components of the body
such as total body water (TBW) and fat free mass (FFM). The InBody 520TM is done with the
subject standing upright, stepping on two foot electrodes and holding on to two handles with two
thumb electrodes. The InBody S10TM is done while the subject is in the supine position with an
electrode around each ankle and two electrodes on each on, one on the thumb and one on the
middle finger. The InBody 520TM takes approximately 90 seconds to complete. There are no
risks associated from the very minimal electrical current omitted during the testing.
X-rays will be used during this research study to measure body composition from the DXA. The
cumulative radiation exposure from this test is approximately 1.5 mrem, which is a very minimal
amount of radiation. For comparison, natural daily background radiation exposes humans to
approximately .7 mrem per day, a flight in a commercial airplane across the continental United
States has a radiation exposure of approximately four to six mrem and traditional X-rays can
range anywhere from 25 mrem up to 270 mrem.
I understand that all information and data collected in this study will be kept confidential by a
specific code number, which will be used for identification. In addition, a master list of of code
numbers will be locked up in a separate location from any data collection information and only
available to the researchers. I am voluntarily making the decision to participate in this research
study, signified by my signature below.
I understand that my consent to participate in this study does not constitute a waiver of any legal
rights or redress I may have as a result of my participation. I acknowledge that I have received a
copy of this informed consent form.
I __________________________________ agree to participate in this study.
Print Name
___________________________________________
Signature of Participant

_______________
Date
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___________________________________________
Signature of Principal Investigator

_______________
Date
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Appendix D
INITIAL SCREENING QUESTIONNAIRE
Name: ________________________________________________________________________
Age:_____________________________

Sex: _____________________________________

Height: ______________________ Weight:__________________________________________
Do you have any metal implanted from surgery such as screws, plates, rods, etc? ____________
Do you currently have a pacemaker implanted? _______________________________________
Females: Are you currently pregnant? _______________________________________________
** Negative pregnancy will be confirmed by pregnancy test day of testing.
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Appendix E
Pretest Guideline Checklist
YES

NO

Did the subject refrain from eating at least five hours prior to testing but not more
than 12 hours?

YES

NO

Did the subject refrain from exercise within eight hours prior to testing?

YES

NO

Did the subject refrain from consuming large amounts of liquids within four hours
prior to testing?

YES

NO

Did the subject refrain from consuming caffeine or other diuretics within three
hours prior to testing?

YES

NO

Did the subject refrain from consuming alcohol within twelve hours prior to
testing?

YES

NO

Did the subject refrain from showering directly prior to testing?
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Appendix F
Pretest Guidelines
-

Do NOT eat at least five hours prior to testing but not more than 12 hours.

-

Do NOT exercise within eight hours prior to testing.

-

Do NOT consume large amounts of liquids within four hours prior to testing.

-

Do NOT consume caffeine or other diuretics within three hours prior to testing.

-

Do NOT consume alcohol within twelve hours prior to testing.

-

Do NOT shower directly prior to testing.

